Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

Zhou, DC; Dong, XR; Zhou, Z; Liu, Q

Liu, Q (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410000, Hunan, Peoples R China.

RISK MANAGEMENT AND HEALTHCARE POLICY, 2023; 16 (): 2521

Abstract

Purpose: The market price of adebrelimab, the first Chinese-developed anti-PD-L1 antibody used as a first-line treatment for extensive stage-small-cel......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索